We are pleased to announce that the scientific article "State of the Art in Menopause: Current Best Practice Approaches from the IMS World Congress 2024" has been published in the prestigious journal Climacteric.
This publication is based on the expert roundtable led by our Global Medical Team at the 19th International Menopause Society (IMS) World Congress in Melbourne.
Key Insights from the IMS Congress
Moderated by Prof. James Simon and organized by Zsolt Bosnyak, Chief Medical Officer, and Virna Gamalinda, Global Medical Director, in collaboration with BH Germany represented by Martina Ehmen, the roundtable brought together eight leading international experts to discuss the latest best practices in menopause management.
The article highlights several key topics including Implementing Guidance in Routine Clinical Practice:
1. Cardiovascular Health in Menopausal Women
• Recognizing sex-specific risk factors such as gestational diabetes and pregnancy-induced hypertension.
• Understanding the role of Menopausal Hormone Therapy (MHT) in managing cardiovascular risks, though not as a primary prevention.
2. Osteoporosis Prevention and Therapy
• Emphasizing early intervention, as bone loss begins during menopausal transition.
• Positioning MHT as a key intervention for maintaining bone health and reducing fracture risk.
3. Urogenital and Sexual Health
• Highlighting local estrogen therapy as an effective treatment for vaginal atrophy and other genitourinary symptoms.
• Exploring the benefits of testosterone therapy for postmenopausal women with hypoactive sexual desire disorder.
4. Mid-Life Changes and Work-Life Balance
• Examining the impact of menopause on sleep, cognition, and mental health and the role of cognitive behavioral therapy (CBT) and MHT in alleviating symptoms.
• Addressing workplace challenges related to menopause and the need for greater awareness and support.
5. Therapeutic Management of Perimenopause
• It often presents with symptoms that are severe and hard to manage, including VMS, vaginal dryness, adverse mood and sleep changes.
• MHT is considered the mainstay of VMS treatment. Transdermal MHT offers a distinct safety advantage over oral formulations.
6. MHT and Cancer Risks
• Advocating for a personalized approach in women with a history of cancer.
• Recommending non-hormonal treatments as the first-line therapy for managing symptoms in hormone-sensitive cancers.
A Testament to Besins Healthcare’s Commitment to Science
The publication of this article in Climacteric reinforces Besins Healthcare’s dedication to advancing menopause and providing scientific resources to improve women's health worldwide. This resource will support healthcare professionals in applying the latest insights from the IMS Congress.
Read the full article here
A special thank you to all the experts who contributed to this important publication, further strengthening Besins Healthcare’s leadership in menopause care.
